For the quarter ending 2026-03-31, TMDX had -$8,689K decrease in cash & cash equivalents over the period. -$12,124K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 7,315 | 105,383 | 24,319 | 60,589 |
| Depreciation and amortization expense | 11,864 | 7,468 | 6,849 | 12,868 |
| Stock-based compensation expense | 9,952 | 9,395 | 9,136 | 18,330 |
| Deferred taxes | 1,067 | -83,543 | - | - |
| Non-cash interest expense and end of term accretion expense | - | 3,080 | 2,374 | 1,578 |
| Non-cash interest expense | 4,593 | - | - | - |
| Loss on disposal of fixed assets | - | 0 | 0 | -80 |
| Non-cash lease expense | - | 585 | 550 | 997 |
| Non-cash operating lease expense | 610 | - | - | - |
| Unrealized foreign currency transaction (gains) losses | -486 | 141 | 8 | 1,473 |
| Accounts receivable | 6,520 | 3,582 | -24,148 | 6,616 |
| Inventory | 3,896 | 6,531 | 6,902 | -5,717 |
| Prepaid expenses and other current assets | -1,961 | -1,060 | 5,900 | -1,081 |
| Other non-current assets | 155 | 13 | 6 | 4 |
| Accounts payable | 1,126 | -2,064 | 2,455 | -410 |
| Accrued expenses and other current liabilities | -3,105 | 6,966 | 13,141 | -2,413 |
| Deferred revenue | 40 | -399 | 1,735 | -192 |
| Operating lease liabilities | -805 | -777 | -740 | -1,378 |
| Net cash provided by (used in) operating activities | 24,533 | 34,513 | 69,573 | 88,754 |
| Purchases of property, plant and equipment | 36,657 | 15,514 | 7,624 | 36,113 |
| Net cash used in investing activities | -36,657 | -15,514 | -7,624 | -36,113 |
| Proceeds from issuance of common stock upon exercise of stock options | 2,212 | 3,099 | 1,816 | 8,831 |
| Proceeds from issuance of common stock in connection with employee stock purchase plan | 1,688 | 0 | 1,963 | 1,286 |
| Tax withholding payments related to net settlement of restricted stock units | 138 | 0 | 138 | - |
| Net cash provided by financing activities | 3,762 | 3,099 | 3,641 | 10,117 |
| Effect of exchange rate changes on cash and restricted cash | -327 | 94 | 9 | 1,167 |
| Net decrease in cash and restricted cash | -8,689 | 22,192 | 65,599 | 63,925 |
| Cash and restricted cash, beginning of period | 488,866 | 466,674 | 1,578 | - |
| Cash and restricted cash, end of period | 480,177 | 488,866 | 466,674 | - |
TransMedics Group, Inc. (TMDX)
TransMedics Group, Inc. (TMDX)